Bristol Myers, Eisai and Lundbeck ally to bring down blood-brain barrier FDA approves oral pellet version of Gilead's Epclusa for use in young hepatitis C patients Verona sells Chinese rights to inhaled drug for $40M upfront InCarda posts midphase data on inhaled atrial fibrillation drug Eli Lilly pins injectable migraine med Emgality against Biohaven's oral rival Nurtec ODT in head-to-head study Featured Story | By Nick Paul Taylor Bristol Myers Squibb, Eisai and Lundbeck have formed a precompetitive collaboration with Harvard University to discover better ways to get drugs across the blood-brain barrier. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor The FDA has approved an oral pellet formulation of Gilead’s hepatitis C drug Epclusa for use in young children who cannot swallow tablets. Gilead secured approval for two strengths of the formulation in children as young as three years of age. read more By Nick Paul Taylor Verona Pharma has sold the rights to chronic obstructive pulmonary disease (COPD) drug candidate ensifentrine in greater China to Nuance Pharma for $40 million upfront. A nebulized formulation of the dual PDE3-PDE4 inhibitor is in phase 3 development as a maintenance treatment for COPD. read more By Nick Paul Taylor InCarda Therapeutics has reported phase 2 trial data on its inhaled challenger to Pfizer’s intravenous anti-arrhythmic drug Corvert. The readout sets InCarda up to start a single pivotal trial in the third quarter and deliver data from the study in the second half of next year. read more By Noah Higgins-Dunn Eli Lilly will test its injectable migraine antibody Emgality against Biohaven Pharmaceuticals' oral Nurtec ODT to treat episodic migraine patients in a late-stage, head-to-head study read more Resources Sponsored by: Clinical Ink For faster deployment, improved patient engagement, and better-quality data — go where your patients are. GO BYOD with Lunexis™ from Clinical Ink. Sponsored by: BBK Worldwide Create a more diverse and inclusive clinical trial enrollment and engagement environment by learning the barriers to participation and the strategies to overcome them. Sponsored by: Thermo Fisher Scientific Autologous cell and gene therapy workflows involve isolating cells from an individual, engineering the cells, expanding and concentrating them, and infusing them back into the patient. Optimized automation of certain steps of the workflow may decrease hands-on time and the cost of the cell manufacturing process. Sponsored By: Veeva Learn how to develop a standards program that has your full team’s buy-in and improves the efficiency and quality of your clinical trials. Sponsored By: Oracle Health Sciences New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19. Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process intesification Sponsored By: August Bioservices How has COVID-19 impacted CRO/CDMO customer (dis)satisfaction and outsourcing decisions for pharma and biotech companies in 2021 and beyond? Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process development and manufacturing of your novel molecule Sponsored By: Remarque Systems Remarque Systems consolidates data, then layers on visualization and automated metrics to generate consistent, actionable data insights in real-time. Click here for more info. Sponsored By: Within3 We enable virtual work — offering over-time sessions where participants are more focused, insights are more diverse and business goals are met. Sponsored by: Catalent Discover the current state of patient-focused dose design through clinical evidence, real-world case studies and patient preference-driven drug design solutions that can help develop better treatments and successful real-world outcomes. Sponsored by: Catalent This eBook features insights from experts in the industry on patient-centric drug development challenges and strategies on advancing drug design and development effectively. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Next Gen: What’s beyond the leading edge of biotech and pharma? June 22-23, 2021 | Virtual Event | 